

I hereby certify that this correspondence is being delivered
by hand to:

Technology Center 1600
Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Atty Docket No.: 015270-006430US
Client Ref. No.: 228-US-NEW

201
LP

On _____

TOWNSEND and TOWNSEND and CREW LLP

By: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John P. Anderson *et al.*

Application No.: 09/471,669

Filed: December 24, 1999

For: BETA-SECRETASE ENZYME
COMPOSITIONS AND METHODS

Examiner: Malgorzata A. Walicka

Art Unit: 1652

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

RECEIVED
CENTER 1600/2900
02 DEC -9 PM 1:15

RECEIVED
DEC 1 0 2002
TECH CENTER 1600/2900

Technology Center 1600
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed by the Examiner in an undated communication, Applicants submitted the required paper copy and computer readable copy of the Sequence Listing on July 28, 2000. Upon closer examination it was observed that this Sequence Listing contained improper presentation of some sequences. These imperfections have been corrected in the Substitute Sequence Listing.

Please find enclosed a Substitute Sequence Listing in the paper and computer readable format to replace the original Sequence Listing and disk mailed on July 28, 2000.

Please add the enclosed paper copy of the sequence listing, page numbers 1-54, at the end of the application and amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

D